EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Extracardiac Tracer Uptake on Technetium-99m–Labeled Pyrophosphate Scintigraphy in Patients With Non-transthyretin Cardiac Amyloidosis

Koji Takahashi, Daisuke Sasaki, Nobuhisa Yamamura, Takaaki Iwamura, Yoshiyasu Hiratsuka, Shuhei Yamamoto, Sohei Kitazawa, Mitsuharu Ueda, Mako Yoshino, Daijiro Enomoto, Hiroe Morioka, Shigeki Uemura und 3 weitere

Clinical Nuclear Medicine Open · 2025

DOI: 10.1097/nm9.0000000000000025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Nuclear Medicine Open, 2025. Verfasst von Koji Takahashi und 14 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In patients with wild-type transthyretin (ATTRwt) amyloidosis, formerly known as senile systemic amyloidosis, ATTRwt deposition in soft tissues causes orthopedic diseases several years before cardiac manifestations. However, few studies have demonstrated extracardiac ATTRwt deposition before myocardial deposition through imaging modalities. This retrospective study aimed to determine whether technetium-99m–labeled pyrophosphate ( 99m Tc-PYP) is taken up by extracardiac tissue, particularly skeletal muscle, in patients with non-ATTR cardiac amyloidosis (CA), defined as no myocardial tracer uptake. Patients and Methods: Chest-centered and abdomen-centered 99m Tc-PYP scintigraphy images were obtained 2 hours after the intravenous injection of the tracer (20 mCi). First, the frequency of 99m Tc-PYP uptake in the internal oblique muscle (IOM)—where an association between tracer uptake and histologic ATTRwt deposition has been reported in patients with ATTRwt-CA—was investigated in patients with non–ATTR-CA. Second, the study participants were divided into 2 subgroups according to the presence (positive group) or absence (negative group) of 99m Tc-PYP uptake in the muscle, and the differences in clinical characteristics were evaluated between the two subgroups.

Results

Overall, 125 patients (median age, 85 y; interquartile range, 77–89 y; 51.2% male individuals) were included. The frequency and multivariate predictors of 99m Tc-PYP uptake in the IOM were 35.2% and older age (odds ratio, 2.27; 95% CI, 1.04–4.92; P = 0.039), respectively.

Conclusions

In patients with non–ATTR-CA, the greatest predictor of 99m Tc-PYP uptake in the IOM, suspected to show ATTR deposition, was advanced age. Follow-up of these patients may lead to early detection of ATTR-CA.

Zitieren

APA

Takahashi, K., Sasaki, D., Yamamura, N., Iwamura, T., Hiratsuka, Y., Yamamoto, S., Kitazawa, S., Ueda, M., Yoshino, M., Enomoto, D., Morioka, H., Uemura, S., Okura, T., Sakaue, T., & Inoue, K. (2025). Extracardiac Tracer Uptake on Technetium-99m–Labeled Pyrophosphate Scintigraphy in Patients With Non-transthyretin Cardiac Amyloidosis. Clinical Nuclear Medicine Open. https://doi.org/10.1097/nm9.0000000000000025

Vancouver

Takahashi K, Sasaki D, Yamamura N, Iwamura T, Hiratsuka Y, Yamamoto S, et al. Extracardiac Tracer Uptake on Technetium-99m–Labeled Pyrophosphate Scintigraphy in Patients With Non-transthyretin Cardiac Amyloidosis. Clinical Nuclear Medicine Open. 2025. doi:10.1097/nm9.0000000000000025

BibTeX
@article{Takahashi2025,
  author = {Takahashi, Koji and Sasaki, Daisuke and Yamamura, Nobuhisa and Iwamura, Takaaki and Hiratsuka, Yoshiyasu and Yamamoto, Shuhei and Kitazawa, Sohei and Ueda, Mitsuharu and Yoshino, Mako and Enomoto, Daijiro and Morioka, Hiroe and Uemura, Shigeki and Okura, Takafumi and Sakaue, Tomoki and Inoue, Katsuji},
  title = {Extracardiac Tracer Uptake on Technetium-99m–Labeled Pyrophosphate Scintigraphy in Patients With Non-transthyretin Cardiac Amyloidosis},
  journal = {Clinical Nuclear Medicine Open},
  year = {2025},
  doi = {10.1097/nm9.0000000000000025}
}
Kostenlos starten →